The Use of Diffusion Weighted Imaging to Detect Structural Biomarkers in Recently-Diagnosed Parkinson’s Disease Patients
Objective: To quantify biomarkers for recently-diagnosed PD patients in the midbrain and their dopaminergic connections to the striatum. Background: The development of improved PD treatments…Functional Biomarkers of Parkinson’s Disease: Changes in Brain-Wide Network Connectivity in Default Mode and Fronto-Parietal Control Networks
Objective: Parkinson’s disease (PD) is a neurological disorder with no reliable biomarkers. We aimed to investigate naturalistic paradigms as functional biomarkers that distinguish between PD…Focus on the Locus: Ultra-high field MRI evaluation of locus coeruleus structure and function in Parkinson’s Disease
Objective: To develop an imaging protocol for 7 tesla magnetic resonance imaging (MRI) that captures the structural and functional consequences of locus coeruleus (LC) neurodegeneration.…Imaging correlates of impaired self-awareness of cognitive deficits in Parkinson’s disease
Objective: To discover the neural basis of impaired self-awareness of cognitive deficits (ISA-cog) in Parkinson’s disease (PD) patients with mild cognitive impairment (MCI). Background: Anosognosia…Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy
Objective: To test how regional tau pathology and neuroinflammation are associated with clinical severity and survival in progressive supranuclear palsy (PSP). Background: The abnormal aggregation…Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up
Objective: To examine the clinical and biological characteristics of participants with scans without evidence of dopaminergic deficit (SWEDD) during a two-year follow-up. Background: Study participants…Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?
Objective: To assess if there are differential metabolic brain patterns among Progressive Supranuclear Palsy(PSP) clinical variants and between them and Parkinson’s disease patients (PD). Background:…11C-PBB3 PET in PD: does alpha-synuclein pathology start in axonal terminals?
Objective: To use 11C-PBB3 PET binding to monitor alpha-synuclein (a-syn) pathology in PD subjects in vivo. Background: In previous work we have shown binding of…Investigation of 531 cases of neuromelanin sensitive imaging, about its characteristics by disease
Objective: To investigate the utility of Neuro-Melanin sensitive MRI (NMI) by 3T MRI for diagnosis, the relationship and severity in Parkinson's disease (PD) and related…Automated Interpretation of FP-CIT-SPECT images based on Artificial Intelligence
Objective: Our objective is to develop an AI-based approach to automatically rate FIP-CIT-SPECT data. Background: FP-CIT-SPECT visualizes the integrity of nigro-striatal dopaminergic synapses in vivo.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.